Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 22439936)

1.

Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells.

Engelhardt JJ, Boldajipour B, Beemiller P, Pandurangi P, Sorensen C, Werb Z, Egeblad M, Krummel MF.

Cancer Cell. 2012 Mar 20;21(3):402-17. doi: 10.1016/j.ccr.2012.01.008.

2.

The emerging understanding of myeloid cells as partners and targets in tumor rejection.

Broz ML, Krummel MF.

Cancer Immunol Res. 2015 Apr;3(4):313-9. doi: 10.1158/2326-6066.CIR-15-0041. Review.

PMID:
25847968
3.

Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.

Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van't Veer LJ, Sperling AI, Wolf DM, Krummel MF.

Cancer Cell. 2014 Nov 10;26(5):638-52. doi: 10.1016/j.ccell.2014.09.007. Epub 2014 Oct 16.

PMID:
25446897
4.

Tumour immunology: the new midfielders in the tumour microenvironment.

Villanueva MT.

Nat Rev Immunol. 2014 Dec;14(12):778-9. doi: 10.1038/nri3781. No abstract available.

PMID:
25421696
5.

Microenvironment: the new midfielders in the tumour microenvironment.

Villanueva MT.

Nat Rev Cancer. 2014 Dec;14(12):765. doi: 10.1038/nrc3861. Epub 2014 Oct 30. No abstract available.

PMID:
25355376
6.

Dendritic cells: In vitro culture in two- and three-dimensional collagen systems and expression of collagen receptors in tumors and atherosclerotic microenvironments.

Sprague L, Muccioli M, Pate M, Singh M, Xiong C, Ostermann A, Niese B, Li Y, Li Y, Courreges MC, Benencia F.

Exp Cell Res. 2014 Apr 15;323(1):7-27. doi: 10.1016/j.yexcr.2014.01.031. Epub 2014 Feb 22.

PMID:
24569142
7.

ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.

Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ.

Cancer Immunol Immunother. 2014 May;63(5):437-48. doi: 10.1007/s00262-014-1525-z. Epub 2014 Feb 15.

PMID:
24531387
8.

Dendritic cells, inflammation, and breast cancer.

Palucka K, Coussens LM, O'Shaughnessy J.

Cancer J. 2013 Nov-Dec;19(6):511-6. doi: 10.1097/PPO.0000000000000007. Review.

9.

Inactivation of tumor-specific CD8⁺ CTLs by tumor-infiltrating tolerogenic dendritic cells.

Harimoto H, Shimizu M, Nakagawa Y, Nakatsuka K, Wakabayashi A, Sakamoto C, Takahashi H.

Immunol Cell Biol. 2013 Oct;91(9):545-55. doi: 10.1038/icb.2013.38. Epub 2013 Sep 10. Erratum in: Immunol Cell Biol. 2013 Nov-Dec;91(10):665.

10.

Regulatory T cells, dendritic cells and neutrophils in patients with renal cell carcinoma.

Minárik I, Lašťovička J, Budinský V, Kayserová J, Spíšek R, Jarolím L, Fialová A, Babjuk M, Bartůňková J.

Immunol Lett. 2013 May;152(2):144-50. doi: 10.1016/j.imlet.2013.05.010. Epub 2013 May 27.

PMID:
23721909
11.

Cell-extrinsic effects of the tumor unfolded protein response on myeloid cells and T cells.

Zanetti M.

Ann N Y Acad Sci. 2013 May;1284:6-11. doi: 10.1111/nyas.12103. Review.

PMID:
23651187
12.

Dynamic imaging reveals promiscuous crosspresentation of blood-borne antigens to naive CD8+ T cells in the bone marrow.

Milo I, Sapoznikov A, Kalchenko V, Tal O, Krauthgamer R, van Rooijen N, Dudziak D, Jung S, Shakhar G.

Blood. 2013 Jul 11;122(2):193-208. doi: 10.1182/blood-2012-01-401265. Epub 2013 May 1.

13.

Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.

Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S, Ferris RL.

Clin Cancer Res. 2013 Apr 1;19(7):1858-72. doi: 10.1158/1078-0432.CCR-12-2426. Epub 2013 Feb 26.

14.

Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.

Henry JY, Labarthe MC, Meyer B, Dasgupta P, Dalgleish AG, Galustian C.

Immunology. 2013 Jul;139(3):377-85. doi: 10.1111/imm.12087.

15.

Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.

Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Cruz LJ, Lambeck AJ, Figdor CG, de Vries IJ.

Blood. 2013 Jan 17;121(3):459-67. doi: 10.1182/blood-2012-06-435644. Epub 2012 Dec 4.

16.

Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.

Bhargava A, Mishra D, Banerjee S, Mishra PK.

Immunotherapy. 2012 Jul;4(7):703-18. doi: 10.2217/imt.12.40. Review.

PMID:
22853757
17.

VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics.

Lund AW, Duraes FV, Hirosue S, Raghavan VR, Nembrini C, Thomas SN, Issa A, Hugues S, Swartz MA.

Cell Rep. 2012 Mar 29;1(3):191-9. doi: 10.1016/j.celrep.2012.01.005. Epub 2012 Feb 23.

18.

Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.

Spear P, Barber A, Rynda-Apple A, Sentman CL.

J Immunol. 2012 Jun 15;188(12):6389-98. doi: 10.4049/jimmunol.1103019. Epub 2012 May 14. Erratum in: J Immunol. 2014 Aug 1;193(3):1513.

19.

Myeloid suppressor cells and immune modulation in lung cancer.

Srivastava MK, Andersson Å, Zhu L, Harris-White M, Lee JM, Dubinett S, Sharma S.

Immunotherapy. 2012 Mar;4(3):291-304. doi: 10.2217/imt.11.178. Review.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk